Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer.

about

Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer.

Item

http://www.wikidata.org/entity/Q40111881

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer.

@en

type

Item

label

Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer.

@en

prefLabel

Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer.

@en

P1476

Pleural Effusion Caused by Bacillus Calmette-Guérin Immunotherapy for Bladder Cancer.

@en

P2093

Adam M Spivak

http://www.w3.org/2001/XMLSchema#string

Brian Kendall

http://www.w3.org/2001/XMLSchema#string

Jonathan Boltax

http://www.w3.org/2001/XMLSchema#string

Tara Rachakonda

http://www.w3.org/2001/XMLSchema#string

P2860

Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature

Immunological basis in the pathogenesis and treatment of bladder cancer

Mycobacterium bovid infection of total knee arthroplasty after bacille Calmette-Guérin therapy for bladder cancer.

Differences between a probable and proven BCG infection following intravesical instillations: 16 years experience in a tertiary care hospital.

Systemic BCG infection in a patient with pancytopaenia and fever 9 years after intravesical BCG administration for bladder cancer.

[Risk of complications during endovesical treatment with BCG for superficial tumor of the bladder].

Incidence and treatment of complications of bacillus Calmette-Guerin intravesical therapy in superficial bladder cancer.

Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L

BCGiosis as a presenting feature of a child with chronic granulomatous disease.

Optimal treatment of systemic bacillus Calmette-Guérin infection: investigations in an animal model.

P304

ofx126

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.1093/OFID/OFX126

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28761898

http://www.w3.org/2001/XMLSchema#string

P932

5534218

http://www.w3.org/2001/XMLSchema#string